Jeff Eiseman
Long only, deep value, special situations

PharmAthene Is A Bargain: Significance Of Recent Legal, Pipeline, And Merger Developments

Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

PharmAthene (NYSEMKT:PIP) is poised to jump. Three recent developments have affected its stock price:

  • the flu product of its prospective merger partner (Theraclone Sciences) failed to reach its clinical trial's primary endpoint, after which the Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) declined funding;
  • PharmAthene terminated its merger with Theraclone; and
  • the FDA placed a clinical hold on SparVax, PharmAthene's anthrax product.

There has also been a lack of news about the seven-year legal battle with SIGA Technologies (NASDAQ:...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
WITH SEEKING ALPHA PRO, INVESTORS CAN ALSO:
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details